Estudio post EMPA-KIDNEY_El Resumen Visual

El estudio post EMPA-KIDNEY, evaluó los efectos de la empagliflozina en pacientes con enfermedad renal crónica. Los hallazgos mostraron que este tratamiento no solo proporcionó beneficios cardiorrenales significativos durante la fase activa del estudio, sino que también mantuvo estos efectos positivos por hasta 12 meses después de la interrupción del tratamiento. 

 Revisa el resumen visual realizado por Oscar Durón y únete a la conversación en nuestro próximo #NephJC

🤔 Empagliflozin in acute decompensated heart failure

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Voors, Nature Medicine 2023)

🤔 EMPA KIDNEY analysis by CKD diagnosis

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)

🤔 EMPA Kidney sub-group analysis by DM and ACR status

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)

🤔 Flozination reduces kidney stones

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes (JAMA 2024)

Flozins strike again!

If you missed the biggest NephJC of the year, at least read the highlights here.

If you only read one #TenTweetNephJC this year, make it this one.

EMPA-KIDNEY is one of those landmark trials it is worth knowing inside-out, but you can still rapidly catch up on the key findings & author tweetchat secrets in the thread below👇 pic.twitter.com/VL2u8BoCLw

— Nephrology Journal Club (@NephJC) November 22, 2022